The interaction of pro-and antiapoptotic BCL-2 proteins determines MOMP as a critical decision point in the mitochondrial pathway of apoptosis 1 . If MOMP occurs, proteins of the mitochondrial intermembrane space, including cytochrome c (cyt c), trigger caspase activation and apoptosis 2 . Even if caspase activity is blocked or disrupted, the cell usually succumbs to bioenergetic catastrophe as a consequence of MOMP 3 . Therefore, the control of MOMP by BCL-2 proteins is central to the understanding of this major pathway of cell death.
a r t i c l e s
The interaction of pro-and antiapoptotic BCL-2 proteins determines MOMP as a critical decision point in the mitochondrial pathway of apoptosis 1 . If MOMP occurs, proteins of the mitochondrial intermembrane space, including cytochrome c (cyt c), trigger caspase activation and apoptosis 2 . Even if caspase activity is blocked or disrupted, the cell usually succumbs to bioenergetic catastrophe as a consequence of MOMP 3 . Therefore, the control of MOMP by BCL-2 proteins is central to the understanding of this major pathway of cell death.
During MOMP, the proapoptotic BCL-2 effector proteins BAK and BAX are responsible for the permeabilization event 4 , and without these neither MOMP nor the engagement of the mitochondrial pathway of apoptosis occurs 5, 6 . BAK and BAX reside in cells in inactive forms and upon activation oligomerize and insert into the membrane, causing permeabilization and thus apoptosis. One step in this oligomerization appears to involve the exposure of one of the BH domains, BH3, which then binds the canonical hydrophobic groove of another BAK or BAX molecule 7, 8 . This groove, present in the antiapoptotic and proapoptotic effector BCL-2 proteins, binds BH3 and often the C-terminal helix of the protein and is called the BC groove 9 . Antiapoptotic BCL-2 proteins, such as BCL-2, BCL-xL and MCL-1, can bind the BH3 of active BAK or BAX, and this is one way in which they block MOMP and apoptosis 9, 10 .
Proapoptotic effector and antiapoptotic BCL-2 proteins are regulated by a subfamily of proteins that share only the BH3 region ('BH3-only proteins') 11 . Some of these, particularly BID and BIM, are capable of activating BAK and BAX 12, 13 and are 'direct activators' 14 . All of the BH3-only proteins bind BCL-2, BCL-xL or MCL-1 (ref. 9 ), but the sequestration of BID and BIM is another way in which antiapoptotic BCL-2 proteins block apoptosis 9, 10 .
Little is known regarding how BID and BIM trigger the activation of BAK and BAX. Peptides corresponding to the BH3 regions can be modified by internal cross-links to form BH3 stabilized α-helices of BCL-2-family proteins (SAHB) 15 , and these show enhanced binding to and activation of proapoptotic effectors 16, 17 . A BIM or BAX SAHB can bind a 'trigger site' in BAX that is topologically opposite the BC groove, which suggests that this interaction causes the downstream conformational changes that displace the BAX C-terminal helix from the BC groove, promoting MOMP 16, 17 .
To gain insights into the direct activation of BAK during apoptosis, here we characterize the structure of a recombinant, soluble BAK 18 bound by its BC groove to a BH3 SAHB of BID and describe conformational changes that accompany this binding.
RESULTS

BID binding at the BC groove of BAK
To characterize the BID SAHB-BAK interaction, we used a truncated, soluble human recombinant BAK (cBAK, residues 15-186) 18 . For the SAHB of BID BH3, we positioned the stabilizing bridge at sites along the hydrophilic side of the amphipathic BID BH3 helix to minimally interfere with the effector-binding interface (Fig. 1a,  Supplementary Fig. 1a and Supplementary Table 1 ) 15, 19, 20 . Unlike conventional BH3 peptides, BID SAHBs are helical, as indicated by CD (Supplementary Fig. 1b ) and as described 15 . Positioning the 'staple' within the C-terminal half of BID BH3 (SAHBa) enhanced BAK binding by approximately ten-fold over that of the unstapled counterpart, producing a 1:1 complex, as assessed by sedimentation velocity analytical ultracentrifugation (AUC) analysis (Supplementary  Tables 1 and 2 and Fig. 1a ). The addition of SAHBa to enriched mitochondria induced the release of cyt c in a BAK-dependent manner a r t i c l e s ( Fig. 1b and Supplementary Fig. 1c ; wild-type mitochondria contain BAK but not BAX). The TROSY spectra of 15 N-cBAK in complex with SAHBa or its unstapled counterpart were very similar, which showed that the bridge did not induce significant changes in cBAK conformation but instead improved the affinity of the interaction ( Fig. 1c and Supplementary Fig. 1d,e) .
We characterized the SAHBa-cBAK complex in solution by NMR spectroscopy. A comparison of chemical-shift values for apo-cBAK 18 and those for the SAHBa-cBAK complex suggested that SAHBa bound within the BC groove of BAK (Fig. 1d,e) . Additional SAHBa binding-induced chemical-shift perturbations mapped to residues on either side of the BC groove in helices α1 and α6 that did not contact the peptide, probably as a result of changes in the chemical environment as the groove opened to accommodate the incoming SAHBa (Fig. 1c-e) . These observations were confirmed through determination of the solution structure of 13 C and 15 N doublelabeled cBAK bound to unlabeled SAHBa. An ensemble of the 20 lowest-energy structures exhibited a backbone-atom r.m.s. deviation of 0.53 Å ( Table 1 and Supplementary Fig. 2a,b) . The lowest-energy conformer is used to represent the 3D structure of the SAHBa-cBAK complex in all the figures.
BID induces opening of the occluded BC groove of BAK
The SAHBa peptide adopts a conformation with six helical turns upon binding within an opened BC groove on cBAK ( Fig. 2 and Supplementary Fig. 2 ). The SAHBa peptide binds the BC groove in an orientation seen previously in structures of complexes between BH3 peptides and antiapoptotic BCL-2 proteins 9 . In all of these complexes, the hydrophobic faces of the amphipathic BH3 helices bind within the BC groove (Fig. 2a,c and Supplementary Fig. 2e,f) . In the SAHBa-cBAK complex, this allowed the bridge-containing hydrophilic residues of SAHBa to face the solvent and limit contact with residues of the BC groove in cBAK (Supplementary Fig. 2b) . Further, the loop between BAK helix α1 and α2 exhibited a disordered conformation compared with that of the BAK crystal structure 18 , although other studies have suggested similar disorder of this loop in apo-BAK (Supplementary Fig. 2a ) 21, 22 .
The SAHBa-cBAK structure displays interactions for the highly conserved Leu90 and Asp95 of BID with a hydrophobic-groove pocket and a charged patch in the BH1 of BAK, respectively ( Fig. 2a and Supplementary Fig. 2c,g ). The side chain of Tyr89 at the end of BAK BH3, positioned centrally to occlude the BC groove in the apo-BAK structure (Fig. 2d) 18 , is displaced by SAHBa, which, in the complex, positions four hydrophobic residues deeply and centrally within the groove: Ile86, Leu90, Val93 and Nle97 (Fig. 2c) . On the opposite side of the groove from Tyr89, BAK BH1 Arg127 and Asn124 form hydrogen bonds with Asp95 and Asp98 of BID, respectively (additional details of SAHBa-cBAK BC-groove binding are in Supplementary Fig. 2 and Supplementary Movies 1 and 2) . The SAHBa-cBAK structure suggests that BID binding to the occluded BC groove is a primary event during BAK activation, thus producing a stable conformer in membrane-free environments.
BID-induced collapse of BAK N-terminal bundle in CHAPS
To study active BAK in cells undergoing apoptosis, we previously used an assay in which conformational changes alter its sensitivity npg a r t i c l e s to calpain proteolysis 10 . In the absence of apoptotic stimulation, native cellular BAK is fully resistant to calpain. Upon activation, BAK becomes susceptible to proteolysis at two positions, at the end of the BH4 and within the BH3 region, thus producing two stable fragments that stretch to the C terminus (Fig. 3a) . Nonionic detergents induce the active conformation of BAK in the absence of direct activators, which manifests as sensitivity to calpain and the appearance of two stable fragments 10 . The small-micelle detergent CHAPS did not induce this conformational change 10 , and we therefore probed the conformation of the BID-cBAK complexes in CHAPS ( Fig. 3 and Supplementary Fig. 3 ). In the absence of detergent, the BID-cBAK complexes, including SAHBa-cBAK, were fully resistant to proteolysis by calpain ( Supplementary  Fig. 3a) . In contrast, in the presence of CHAPS the BH3a-cBAK and SAHBa-cBAK complexes were susceptible to proteolysis by calpain ( Supplementary Fig. 3a,b) . Using this approach, we analyzed structure-activity relationships for BID. The opening of the BC groove of cBAK to accommodate SAHBa suggests that the hydrophobic face of the BID BH3 helix is important for BAK activation. We performed extensive mutagenesis of BID BH3 in the context of active, full-length, cleaved recombinant BID, referred to as NC BID (Fig. 3b,d ; BID is activated through proteolysis within its disordered loop between helix α1 and the BH3-containing helix α2) 23 and SAHBa (Supplementary Fig. 3c ,f and Supplementary Table 1) . Dimethyl sulfoxide or SAHB (5 µM) alone did not permeabilize BAK-knockout mitochondria. BID BH3 hydrophobic-residue replacements by alanine or glycine, including I86A, L90A and M97G, resulted in impaired BAK activation and increased the minimal BID concentration required for BAKmediated MOMP by almost two orders of magnitude (Fig. 3b,d and Supplementary Fig. 3c,f) . Equally potent in disrupting BID function was the A91W substitution on the hydrophilic face of BID BH3, probably acting through clashes of the large tryptophan side chain with the BH1 of BAK. The combined double substitutions I86A L90A and I86A A91W showed an additive effect on BAK-mediated MOMP and active BAK conformation, further disabling BID activation of BAK (Fig. 3b,d and Supplementary Fig. 3c,f) . In contrast, the D98G substitution on the hydrophilic side of the BID BH3, predicted to interact with a charged patch in the BH1 of BAK, affected function less dramatically than did the hydrophobic-residue substitutions (Fig. 3b,d and Supplementary Fig. 3c ,f).
We tested deletions of residues at the N terminus and C-terminal extension in the BID SAHB (Fig. 3c,d and Supplementary Table 1) . N-terminal deletion of four and eight residues sequentially diminished the ability of SAHB to activate BAK (Fig. 3c,d) . Accordingly, deletion of the first four residues ablated BAK binding, as measured by NMR, whereas weak binding and activity were detectable by Inter-residue
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Hydrogen bonds 126 (14) Total dihedral angle restraints 218 ( Tables 1 and 2 ). Addition of three native residues at the C terminus did not significantly improve SAHB binding or activity (Fig. 3c,d ). Our combined mutagenesis and truncation analysis suggests that effective activation of BAK by BID requires critical hydrophobic contacts by BID at the four most central hydrophobic residues, Ile86, Leu90, Val93 and Met97.
Structural basis for a hit-and-run activation mechanism
In contrast to the high-affinity interactions between antiapoptotic BCL-2 proteins and their BH3 ligands (K d ~10 nM) 24, 25 , BAK's direct activation may be governed by a transient hit-and-run mechanism 11, 26 . Accordingly, direct-activator BH3 ligands transiently engage the BC groove of BAK with moderate affinity (K d ~10 µM) to induce the conformational changes seen in the SAHBa-cBAK structure. In the presence of biological membranes, direct-activator BH3-only proteins dissociate from BAK 26 . We tested the hit-and-run model, using engineered direct-activator-effector complexes produced through disulfide-bonding of BID and BAK. We introduced single cysteines in BID BH3 at Ile83, Ile86, Met97, Asp98 and Ile101. Given their minimal effect on NC BID and SAHBa function ( Supplementary  Fig. 3c,e,f) , these cysteines provided disulfide-bond 'trapping' sites in BID. Guided by the SAHBa-cBAK structure, we engineered single cysteines in the BH2 region, proximal to BID Ile101, and produced them in BAK containing serine substitutions at the naturally occurring cysteines (C14S C166S; Fig. 4a,b and Supplementary Fig. 4a,b) .
The efficiency of cross-linking to a BID SAHB containing the I101C substitution (SAHBq; Fig. 4c,d, Supplementary  Fig. 4c and Supplementary Table 1 ) was proportional to the amount of SAHB. At a 2.5-fold molar excess of SAHBq to cBAK (20 µM), L183C and G184C (in cBAK) crosslinked to I101C in SAHBq with ~40-80% efficiency upon oxidation with copper-1, 10-phenanthroline (Cu-Phe) ( Fig. 4d ; the orientation of SAHBq at the BC groove in these complexes is illustrated in Fig. 4a,b) . We also produced an I101C SAHBq adduct to cBAK Cys166 with ~20% efficiency. This 'trap' site, on the face opposite the BC groove, was expected to allow free motion of the SAHB about the disulfide bond without perturbing the access to the BC groove (Fig. 4a) . The oxidized SAHBq-cBAK complexes migrated more slowly than their reduced counterparts during SDS PAGE (Fig. 4d) .
We tested calpain sensitivity of oxidized SAHBq-cBAK complexes in CHAPS, with or without excess SAHBa, to assess their activation conformation. The disulfide-bonded SAHBq-cBAK BH2 adducts, but not the Cys166-targeted adduct, were completely resistant to calpain proteolysis (Fig. 4e,f) . Adding excess SAHBa activated both of the SAHBq-cBAK BH2 complexes (Fig. 4e,f) . These results suggested that SAHBq-cBAK BH2 complexes potently trapped SAHBq at the BC groove, preventing the conformational change associated with calpain sensitivity, whereas the Cys166-targeted complex activated BAK in trans, which supported the hit-and-run model. The SAHBqcBAK BH2 complexes required excess SAHBa to partially displace the trapped SAHBq by competition at the BC groove, as seen in the SAHBa-cBAK structure. This is probably facilitated by the ability of the BAK BH2 to undergo the conformational changes associated with activation and move away from the BH3 (Fig. 4f) .
Oxidation at five-fold molar excess of peptide to cBAK (100 µM) resulted in efficiencies of cross-linking for I101C SAHBq to Supplementary Fig. 3 ).
a r t i c l e s L183C and G184C cBAK of >95% and to Cys166 cBAK of ~50% (Supplementary Fig. 4c) . The efficiently oxidized SAHBq-cBAK complexes were tested by gel-filtration chromatography to assess oligomerization. The L183C and G184C SAHBq-cBAK traps were monomeric and remained so even when a four-fold excess of SAHBa was supplemented (Supplementary Fig. 4d,e) . In contrast, the Cys166 trap displayed a monomeric-to-oligomeric chromatography profile, eluting as species of ~22 kDa to >670 kDa. To probe the accessibility of SAHBq in the L183C and G184C traps, we applied the gel-filtration samples to an Ni 2+ -NTA agarose affinity column preloaded with BCL-xL containing a C-terminal hexahistidine (His 6 ) tag ( Supplementary  Fig. 4f ). Whereas the Cys166 trap was largely retained by the BCL-xL affinity column, both BH2-trapped proteins were not ( Supplementary  Fig. 4f ). This supports the notion that neither the SAHBq nor the BAK BH3 were accessible to BCL-xL in the L183C and G184C traps.
We next tested the activity of purified SAHBq-cBAK traps in MOMP assays. We originally showed that cBAK displays synergism with NC BID during MOMP of mitochondria from BAK-knockout mouse embryonic fibroblasts (MEFs), albeit in a narrow range of concentrations (5-0.5 µM cBAK), probably owing to poor membrane targeting in the absence of the transmembrane region 18 . To accurately assess the activity of the SAHBq-cBAK traps in MOMP assays, we aimed to produce traps devoid of contaminating cBAK species. The Cys166-trap preparations consistently co-purified with contaminating Cys166-Cys166 cBAK dimer (Fig. 4d) . It has therefore remained impossible to accurately assess activity of the Cys166 trap, although it consistently displayed more activity than Cys166 cBAK (Fig. 4g , comparison of C166 and C166 trap). The L183C and G184C traps that flowed through BCL-xL affinity columns provided largely homogeneous preparations (Fig. 4d and Supplementary Fig. 4f) . Consistent with data presented in Figure 4e , the BH2-tethered SAHBq traps were inactive in effecting MOMP in response to NC BID, whereas at similar concentrations the untethered L183C and G184C cBAK showed marked release of cyt c ( Fig. 4g and Supplementary Fig. 4h) . Moreover, addition of the BCL-2 and BCL-xL antagonist ABT-737 (ref. 27 ) failed to enhance the activity of the BH2-tethered traps but augmented that of the untethered cBAK mutants (Fig. 4g) , thus excluding the possibility that contaminating BCL-xL may have prevented their activation. Our structure-based disulfide-bonded SAHBq-cBAK traps support the hit-and-run BAK activation mechanism, which relies on transient engagement of the BC groove by BID.
BAK activation resolved by structure-guided mutagenesis
We generated structure-guided mutants of BAK and examined direct activation, oligomerization and cell death (Fig. 5a,b) . To test function in a cellular system, using a variety of apoptotic stimuli, we stably expressed BAK mutants in BAK and BAX double-knockout (DKO) MEFs (Fig. 5b,c) . Consistent with other studies 7, 28 , mutation of the Supplementary Fig. 4 ). npg a r t i c l e s BH1 residue Gly126 to alanine rendered BAK inactive for apoptosis ( Fig. 5c and Supplementary Fig. 5 ), cyt c release ( Fig. 5d ) and oligomerization (Fig. 5e) . The G126A mutant was expressed at higher levels in DKO MEFs than in wild type and displayed reduced protease sensitivity in enriched mitochondria activated by NC BID (Fig. 5b,f) . Similarly, G126A substitution prevented the expected conformational change in recombinant cBAK as assessed by SAHBa-induced protease sensitivity in CHAPS (Fig. 5g) . Although the affinity of the BID-BAK interaction is an important determinant for BAK direct activation, BID binding to the G126A cBAK, as detected by various methods including AUC and NMR (Supplementary Table 1) , was not sufficient to induce the specific conformational changes seen for SAHBa-wild-type cBAK detected by NMR and the proteasesensitivity assay. In contrast, although an I81A mutation in the BH3 of BAK impaired BAK oligomerization (Fig. 5e) and apoptosis in reconstituted DKO MEFs (Fig. 5c and Supplementary Fig. 5) , it showed potent NC BIDand SAHBa-induced conformational changes, as assessed by protease sensitivity (Fig. 5f,g ). Although Ile81 of BAK makes direct contact with Ile101 of BID, it appears to be dispensable for BID-induced activation of BAK, as it does not contribute significantly to binding or the conformational changes detected by protease sensitivity in CHAPS (Supplementary Table 1 and Fig. 5f,g ). We suggest that upon activation, I81A BAK exposes its BH3 (ref. 10) but may fail to engage in oligomerization mediated by BH3-BC groove interaction 7 , although a structural basis for this is not provided in our study.
The lack of apoptotic activity of both G126A and I81A correlated with their poor ability to mediate MOMP in enriched mitochondria from DKO MEFs reconstituted with the respective mutants (Fig. 5d) . It is notable that wild-type BAK, purified with native mitochondrial membranes from reconstituted DKO MEFs, showed less accumulation of the smaller calpain-resistant fragment upon activation with NC BID than did the I81A mutant (Fig. 5f ). This is a fragment produced by proteolysis within the BH3. In contrast, upon NC BID activation, wild-type BAK mostly accumulated the larger BH3-containing calpain-resistant fragment, possibly because the BH3 was efficiently buried and therefore protected in the oligomer, consistent with the postulated BH3-BC groove oligomerization interface 7 . The decreased oligomerization in the I81A mutant correlated with a higher abundance of the smaller fragment upon proteolysis, which suggests that this region remained exposed in the activated mutant molecule.
Our testing of these and other BAK mutants reconstituted in DKO MEFs, using a diverse array of apoptotic conditions, including tumor necrosis factor-cycloheximide, ultraviolet and actinomycin-D treatments (Fig. 5a-c and Supplementary Fig. 5 ), suggested that BAKmediated apoptosis followed a similar activation route regardless of the specific activation mechanisms engaged. Receptor-mediated apoptosis activated BID to engage the mitochondrial pathway 29 , but the other apoptotic stimuli tested did not, relying instead on additional direct-activator BH3-only proteins such as BIM, which therefore are likely to trigger BAK activation by also engaging the BC groove 3 .
NOXA and BAD are not direct BAK activators
A long-standing issue in the BCL-2 family's regulation of MOMP has been the unpredictable specificity of BH3-only direct activators for the effectors BAK and BAX. To date, BID and BIM have remained the two most potent direct activators of both BAK and BAX 9, 25 , although reports have potentially implicated PUMA 30, 31 and NOXA 28, 32 as direct activators of the effectors. Our structural analysis provided an opportunity to test the direct-activation function on the basis of the specificity of BID BH3 for the trigger site in BAK. After modeling the BH3 region of BAD and NOXA over that Supplementary Fig. 5 ).
npg a r t i c l e s of BID in the SAHBa-cBAK complex, we predicted that BAD and NOXA BH3 would produce significant clashes with the BC groove of BAK (Fig. 6a) . The BAD BH3 would project four residues corresponding to I86(W), G94(S), M97(F) and I101(F) within 2 Å of BCgroove residues in BAK; the first three N-terminal residues represent the minimal BH3 core required for potent direct activation by BID (Fig. 6a,b) . Similarly, NOXA BH3 would project two residues within 2 Å of the BC groove, corresponding to V93(F) and I101(Q), the latter representing a hydrophobic-to-polar substitution (Fig. 6a,b) . We therefore tested BAD and NOXA BH3 peptides in MOMP assays using enriched mitochondrial fractions from BID and BIM doubleknockout liver ( Fig. 6 and Supplementary Fig. 6 ). In contrast to BID BH3a, NOXAa and BADa peptides were largely inactive, even at 50 µM (Fig. 6c) . Furthermore, we found that NOXAa and BADa peptides were unable to activate cBAK in the protease-sensitivity assays (Fig. 6d) . Moreover, the stapled NOXA SAHB and BAD SAHB were unable to markedly activate BAK, although NOXA SAHB induced weak BAK-mediated MOMP at the highest concentration tested (Fig. 6b,c) . In other studies, membrane disruption by NOXA BH3 peptide was observed at nonphysiologically high concentrations of cBAK (5 µM), although NOXA BH3 did not induce MOMP in digitoninpermeabilized BID and BIM double-knockout MEFs 32 . We systematically engineered NOXA and BAD BH3s to contain BID substitutions at the positions predicted to clash at the BC groove of BAK. By replacing at least four residues with those of BID (denoted NOXA-BIDf and BAD-BIDa in Fig. 6b) , both peptides were weakly active in triggering BAK-mediated MOMP and induced enhanced protease sensitivity of purified cBAK in CHAPS, associated with direct activation (Fig. 6b,c) .
In addition, we tested N-and C-terminal extensions in NOXA that share the minimal BH3 core and observed no evidence of direct BAK activation by any (Supplementary Fig. 6 ). We therefore conclude that BAD and NOXA BH3 are not direct activators of BAK.
DISCUSSION
When the proapoptotic effector proteins BAX and BAK bind the BH3 of BID or BIM, they undergo conformational changes followed by oligomerization and insertion into the outer mitochondrial membranes to effect MOMP. This is the pivotal step in the life-death decision of the mitochondrial pathway of apoptosis, the primary way in which vertebrate cells die. The solution structure of the BID BH3 bound to BAK provides insights into this key activation process. BID BH3 opens a canonical BC groove in BAK in a manner that is notably similar to that of other structures of BH3 binding to antiapoptotic BCL-2-family proteins 9 and evidently to BAX 33 . We validated the activation site of BAK at its BC groove in several structure-function assays in vitro and in cell culture by extensive mutagenesis of both the effector and the direct activator, consistent with studies performed with truncated 28 and full-length forms of BAK 34 . Previously unresolved aspects of Figure 3b . Red and green arrowheads represent the large and small calpain-resistant fragments, respectively. The MOMP and protease-sensitivity assays were performed at the same time for all BH3-BAK complexes, with the exception of NOXA SAHB and BAD SAHB complexes, which were performed at the same time with the peptides in Supplementary Figure 6 . Representative profiles were extracted from larger images. (Additional data are in Supplementary Fig. 6 ). npg a r t i c l e s the role of BID as direct activator 28, 34 emerged from our analysis, including the minimal helical BH3 region required for strong activation of BAK, defined as residues 80-101, which displays extensive interactions at the BC groove of BAK, dominated by the four central conserved hydrophobic residues Ile86, Leu90, Val93 and Met97.
Direct activation of BAK by BID in the absence of membranes induced significant rearrangements in the BH3, which opened the occluded BC groove by destabilizing contacts between the BH1 and BH3 observed in free BAK 18 . Although BH3-BCL-2 family complexes have revealed details of the interactions between BH3 peptides and BC grooves of antiapoptotic BCL-2 proteins, the effectors manifest multilevel binding-induced conformational changes that are significantly augmented by membranes, and activation is poorly correlated with BH3 binding in membrane-free environments although fully dependent on it 33 . The BID-induced BAK activation was fully manifested in the presence of membranes, which support the shedding of the N-terminal bundle of BAK (N terminus to BH3) from the C-terminal bundle (BH3 to C terminus), as indicated by the protease-sensitivity assay in CHAPS detergent. We found that Gly126 mutations in the BH1 of BAK prevented binding-induced conformational changes by BID and thereby prevented all activation events. In contrast, I81A in the BAK BH3 did not prevent these conformational changes that result in protease susceptibility (exposure of the BH3) but did prevent subsequent BAK-BAK oligomerization, MOMP and apoptosis. Therefore, through analysis of these different BAK mutants, critical individual steps in BAK activation were separated: BID BH3 binding, exposure of its BH3, displacement of the BID BH3 by a neighboring BAK BH3 and oligomerization. Our study, though providing no structural insights into oligomerization, is consistent with the proposed activation mechanism of BAX by BID 33 .
In our current understanding of BAK effector activation, BAK is constitutively targeted to the outer mitochondrial membrane by a C-terminal hydrophobic tail, which does not modulate the proapoptotic activity of BAK beyond targeting the membrane 28, 34, 35 . The membrane-tethered BCL-2-like core of BAK contains the necessary structural components associated with MOMP activity (Fig. 7) . BAK is dormant in the absence of apoptotic stimulation, as identified by resistance to calpain proteolysis. The direct activators BID and BIM, but probably not NOXA or BAD, transiently engage the BCL-2 core of BAK in the manner of the SAHBa-cBAK complex during apoptosis. BH3-BC groove binding destabilizes the BCL-2 core by unwinding the BH3 and restructuring the BH1-BH3 hydrophobic core. This creates a deep cavity that potentially weakens the interactions of the long BH4-containing helix α1 at the bottom of the BC groove. Further unwinding of the BCL-2 core is disfavored in membrane-free environments. In native BAK, proximity to the membranes facilitates membrane insertion: BAK's C-terminal bundle (BH3 to C terminus) probably inserts, whereas the N-terminal bundle (N terminus to BH3) unfolds, becoming sensitive to calpain proteolysis. This is facilitated by the hit-and-run nature of the activator BH3, which in the presence of membranes dissociates from the effector BC groove, freeing it for interaction with an adjacent active BAK monomer that supplies its exposed BH3 for a BH3-BC groove oligomerization interface 7, 36 . If hydrophobic residues that may be exposed in active BAK are critical for disruption of the membrane, we can then hypothesize that consolidation of such disruption events may be necessary for MOMP. This, then, may be the function of additional BAK-BAK interactions, such as that described as α6-α6 (ref. 37) . By bringing together local areas of lipid disruption, a 'hole' may develop. Studies have suggested that although permeabilization of a membrane by four molecules of the effector protein BAX is sufficient to release small molecules, approximately 20 activated BAX molecules are needed to release proteins 38 . The precise nature of the interactions that permit such large oligomers to manifest remains unknown.
In contrast to BAK, activation of the effector BAX during MOMP involves an additional step of targeting it from the cytosol to the outer mitochondrial membrane. This step is reversed by BCL-xL and potentially by other antiapoptotic BCL-2 proteins, which help retrotranslocate BAX from the outer mitochondrial membrane to the cytoplasm 39 . Whether mitochondrial translocation requires binding of the BAX trigger site opposite the BC groove 16, 17 or the BC groove itself, as seen for SAHBa-cBAK, has not been clearly resolved, but the binding of the BID BH3 to the BC groove of BAX, in a manner similar to BAK binding, has been resolved at high resolution 33 . Potentially, BAX activation is governed by a hit-and-run mechanism involving sequential transient engagement of both trigger sites, as supported by a recent study that compared the BH3-binding interface of the full-length isoforms of BAX and BAK 34 . BAX triggering also exhibits similarities to BAK, in that engagement of the BAX BC groove by BH3 activators in lipidic milieus alters BAX conformation 40 , such as by straightening hydrophobic helices α5 and α6 (ref. 33 ), which we did not observe in our structure of BID SAHBa-cBAK. Figure 7 Direct activation triggers BAK-mediated MOMP. BAK-mediated MOMP follows a multistep activation-oligomerization mechanism. Dormant BAK is protease resistant, soluble, monomeric and is not kept in check by antiapoptotic BCL-2 proteins 10, 18 . During direct activation in the absence of membranes, BID engages BAK as a soluble, stable 1:1 BH3/BC groove complex that remains resistant to proteolysis. In the presence of the outer mitochondrial membrane or CHAPS (denoted OMM/CHAPS) the 1:1 BID/BAK active complex opens up as it associates with the lipidic milieu, becoming protease sensitive at the BH4 and the BH3. Poorly-understood membrane interactions probably facilitate the dissociation of BID from the BC groove, conforming to the hit-and-run activation mechanism 9, 10 . The BH1 Gly126 mutants block binding-induced conformational changes associated with direct activation. Oligomeric BAK represents the end stage of BAK activation, being membrane associated and presumed to be mediated by two oligomerization interfaces as shown 7, 36, 37 . As the BH3 participates in the BH3-BC groove interface, it becomes buried and resistant to proteolysis, and only the BH4 remains accessible in oligomeric BAK. The BH3 Ile81 mutants block oligomerization by preventing the BH3-BC groove interaction, although inhibitory mutations have not yet been identified at the alternate interface. Further, a structural basis for BH3-to-groove BAX oligomerization has potentially been elucidated 33 . Our study with BAK and the recent efforts with BAX 33 have thus provided missing insights into the nature of the initial events that precipitate the activation of BCL-2 effectors during apoptosis.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The NMR solution structure of SAHBa-cBAK has been deposited in the Protein Data Bank under accession code 2M5B. A related entry has been deposited in the Biological Magnetic Resonance Bank under accession code 19045.
